Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Open-lable, Parallel-controlled, Phase I/II Trial to Study Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With ANCA-associated Vasculitis

NCT05197842 is registered in ClinicalTrials.gov with Staidson (Beijing) Biopharmaceuticals Co., Ltd as lead sponsor.

NCT NCT05197842
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05197842 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Open-lable, Parallel-controlled, Phase I/II Trial to Study Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With ANCA-associated Vasculitis
Lead sponsor
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Phase
Phase 1/2
Overall status
Completed
Start date
February 22, 2022
Completion date
March 19, 2025
Enrollment
93 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

anca-associated vasculitis